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Abstract
Proteome serology may complement expression library-based approaches as strategy utilizing the patients’ immune
responses for the identification pathogenesis factors and potential targets for therapy and markers for diagnosis. Melanoma
is a relatively immunogenic tumor and antigens recognized by melanoma-specific T cells have been extensively studied. The
specificities of antibody responses to this malignancy have been analyzed to some extent by molecular genetic but not
proteomics approaches. We screened sera of 94 melanoma patients for anti-melanoma reactivity and detected
seropositivity in two-thirds of the patients with 2–6 antigens per case detected by 1D and an average of 2.3 per case by
2D Western blot analysis. For identification, antigen spots in Western blots were aligned with proteins in 2-DE and analyzed
by mass spectrometry. 18 antigens were identified, 17 of which for the first time for melanoma. One of these antigens,
galectin-3, has been related to various oncogenic processes including metastasis formation and invasiveness. Similarly,
enolase has been found deregulated in different cancers. With at least 2 of 18 identified proteins implicated in oncogenic
processes, the work confirms the potential of proteome-based antigen discovery to identify pathologically relevant
proteins.
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Introduction
The antigenicity of tumor cells as defined by antibodies in the
sera of cancer patients may provide new insights into the
interrelationship of tumor and immune system, and into the
molecular pathology of the tumor cells. It, thus, may guide the
development of new immune intervention strategies for therapy
and lead to new markers for diagnosis and disease monitoring [1–
8]. The most often employed approach to the identification of
serologically defined antigens so far has been the serological
identification of recombinant expression cloning (SEREX) ap-
proach [9–12]. Hereby, cDNA libraries of tumor tissue, tumor cell
lines or human testis are cloned into l phage expression systems
and screened with sera of cancer patients. SEREX has been
employed to identify serological antigens for melanoma and the
SEREX database (www2.licr.org/CancerImmunomeDB) lists 102
melanoma-associated antigens [9,12,13]. These antigens can be
categorized as differentiation antigens such as tyrosinase, cancer-
testis antigens such as MAGE-1 or NY-ESO, overexpressed gene
products, mutated gene products such as cdk4 or p53 mutants, and
cancer-related autoantigens such as CEBP-c.
In addition to mutation, over- or ectopic expression, antigenicity
of a protein expressed by tumor cells may be determined by post-
translational modifications or altered accessibility. Proteome-based
approaches may complement SEREX approaches in these aspects
and, by displaying and screening with patient sera the proteomes
of tumors in single 2-dimensional electrophoresis gels, provide
information on the scope of tumor cell antigenicity. This
technology has been applied to renal cell carcinoma, ovarian
cancer, pancreatic adenocarcinoma, prostate cancer, gastric
cancer, hepatocellular carcinoma, colon cancer and lung squa-
mous carcinoma [4,14–29]. Using technologies developed for
proteomics research, the antigens are identified by matching
antigen spots in Western blots with protein spots in replica silver-
stained gels, excising these protein spots and identifying the
antigens by peptide mass fingerprint (PMF), peptide fragment
fingerprint (PFF) or de novo peptide sequencing of tryptic fragments
of the proteins [30]. This approach has variously been named
proteome serology [31], immunoproteomics [16], serological
proteome analysis (SERPA) and other [21]. We employed this
combination of Western blot analysis of serological specificities
and mass spectrometry-based protein identification to determine
the range of the immunogenicity of melanoma and the specificities
of the corresponding antibody responses in the patients.
Results
Seroreactivities for melanoma-associated antigens
To determine the frequencies and specificity patterns of
antibody responses to melanoma-associated antigens, we tested
by Western blot analyses the reactivities of sera of 94 patients with
melanoma (see Table S1 for clinical details of the cases) against
protein extracts from the melanoma cell line M-NRT separated by
1-dimensional SDS-PAGE (Figure 1A–C). As controls, the sera of
9 healthy individuals (Figure 1D), and of patients with cutaneous
lymphoma, pancreas carcinoma or visceral leishmaniasis, an
infectious disease that is known to induce responses to autoanti-
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5199Figure 1. Pattern of seroreactivities of melanoma patients, healthy controls and patients with other diseases against the melanoma
cell line M-NRT. Total protein extract of the tumor cells were separated by SDS-PAGE, blotted onto nitrocellulose and probed with the sera of the
melanoma patients (Panels A–C), of healthy control donors (Panel D, sera 102–110) or patients with cutaneous lymphoma (Panel E, sera 96–98),
pancreas carcinoma (Panel E, serum 101) or visceral leishmaniasis (Panel E, sera 111–113). The numbers atop of each lane represent the number of
the sera and are used throughout this report. For comparison, melanoma serum 7 was included in all blots. The Western blot analyses were done with
the sera at a dilution of 1/6 in a multiple channel blotting/Western blot developing chamber for panels A–E. The letters underneath the lanes
indicated the combinations of sera for the multiple probing of the 2D Western blots shown in Figure 2 and summarized in Table 1. Panel F: High-
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signals were relatively weak given the high serum concentrations of
1:6 used for these Western blots. A large number of faint
background bands were detected with the sera of the healthy
controls and patients alike as illustrated with Figure 1F which
shows the Western blots with serum of a healthy donor (Serum
103) and the sera of two melanoma patients (Serum numbers 7
and 18). The Western blots shown in Figure 1F were developed as
individual strips in separate plastic bags at a dilution of 1 in 200
which results in a better definition of the bands but is not suited for
comparative screening of large numbers of sera. The arrows to the
left of the Western blot lanes indicate shared signals found with
patient and control sera alike. The arrows to the right of the
lanes are stronger and indicate unique bands seen only with sera
of melanoma patients. Serum 18 was from the same patient from
whose tumor the melanoma cell line M-NRT had been
established. This Western blot, thus, documents the reactivity
in the autologous combination of tumor cells and serum. All
other sera were from different patients or healthy donors, thus
displaying the reactivity in heterogeneous combination of tumor
cells and serum. The antigens thus detected are, therefore,
expected to be antigens shared between the tumors of the serum
donors and the test tumor cells M-NRT. With nearly two-thirds
of the sera of the melanoma patients prominent bands are
detectable that are not found with the healthy control sera or
that are much stronger than those in the controls (Figure 1). The
numbers of such prominent antigens detected with the reactive
sera ranged between 2 and 6 per patient serum. Their masses
were between 21 and 90 kDa with the bulk of the stronger bands
between 40 and 80 kDa. The patients whose sera were tested
represent, with the exception of ocular melanoma, all forms of
melanoma. The majority of the patients were at stage 3 or 4 of
disease but some were at earlier stages (Table S1). The course of
disease ranged from relatively slow progression to aggressive
disease. Within this range of patients there is no correlation of
the numbers of antigens targeted, and frequencies or pattern of
seropositivity with the clinical conditions. A few stronger
reactivities were seen with the sera of healthy controls and
patients with lymphoma, pancreas carcinoma or Leishmaniasis.
These antigens were different than those detected with the sera
of melanoma patients. In summary, about two-thirds of the
patients had developed prominently detectable antibody re-
sponses against melanoma-associated antigens. The serospecifi-
city patterns, however, were heterogeneous with no antigen that
induced responses in a majority of the patients.
Identification of melanoma-associated antigens that raise
antibody responses
Direct identification of antigens from 1-dimensional SDS-
PAGE gels is not possible because of the complexity of the
protein mixtures at every position in the lanes and difficulties in
exactly aligning Western blots with silver-stained gels. We,
therefore, separated the proteins of the melanoma cell line M-
NRT by 2-dimensional electrophoresis with a pH gradient of 3 to
10 in the isoelectric focusing gels. Nine replica gels were prepared,
eight used for Western blot analyses (Figure 2, panels A–H) and
one for silver staining (Figure 2). Each of the Western blot filter A
through G were probed successively with the sera of 8 melanoma
patients, 56 sera in all. These are all available sera with which
prominent bands were detected by 1DE. Blot H was tested with
the sera of 9 healthy controls. The use of multiple sera per Western
blot is required to expose several antigen spots per blot which is
essential for spot pattern recognition and alignment of silver-
stained proteins with Western blot spots. The serum combinations
for multiple probing were selected to allow good pattern definition
for assigning Western blot spots with protein spots in the silver-
stained gel, and are listed in Table 1 where the numbering of the
sera corresponds to the numbering in Figure 1. The letters
underneath the blot lanes in Figure 1 refer to the 2D Western blots
in Figure 2.
The antigen signals were weak but clearly detectable in the 2-
dimensional Western blots (Figure 2). The blots display 26, 19, 21,
20, 24, 3 and 15 antigen spots in panels A through G, respectively,
altogether 128 antigen spots. With the sera of the healthy controls,
4 antigen spots were detected (Figure 2H). The antigens concur in
numbers and mass distribution with the antigenicity patterns
shown in Figure 1. Fifty-eight of the antigens could be assigned to
protein spots in the silver-stained gels, 17, 9, 4, 12, 9, 1, 4 and 2 for
the blots in Figure 2A through H, respectively. The antigen-
protein assignments were done by first aligning gel and Western
blots by their geometry as defined with artificial marker proteins
spotted on cardinal points of the gels and marker protein spots
detected in the blots after Ponceau S staining. A number of
prominent marker spots were mapped for confirmation by partial
blotting and matching the corresponding Western blots and silver-
stained gels. Then, the spot patterns in the local environments of
the antigens were compared taking spot sizes and shapes into
consideration. The assigned and identified spots are indicated with
arrows and numbered in the Western blots and the corresponding
silver-stained gel shown in Figures 2 and Figure 3. The protein
spots corresponding to the assigned antigens were excised from the
gel, destained and subjected to trypsin digest. The resulting tryptic
fragments were analyzed by peptide mass fingerprint by MALDI-
TOF-MS with MASCOT and PROWL analyses of the peak lists.
Forty-six of the 58 assigned antigens could, thereby, be identified.
Spots number 10, 12, 13 and 24 were found in 2 Western blots,
spots 1 and 5 in 3, spot 2 in 4, spot 3 in 5 and spots 4 and 9 in 6.
All other assigned antigens were found only once. The 46 antigen
spots, thus, represent 18 different antigens.
As examples for the mass-spectrometric identification of the
antigens, the fingerprint mass spectra for spot number 9 identified
as galectin-3, spot number 1 identified as the gelsolin-like actin
filament-capping protein MCP, spot number 4 identified as heat
shock protein 60 (HSP 60) and spot number 28 identified as the
elongation factor EF-Tu are shown in Figure 4A, B, C and D,
respectively. The spectra for the other antigens are provided as
supplementary materials (Figures S1, S2, S3, S4, S5, S6, S7, S8,
S9, S10, S11, S12, S13, S14, S15, S16, S17) as indicated in Table 2
together with the gene identifier numbers, protein-chemical
parameter and the results of the mass-spectrometric identification
for all antigens. In the cases where masses remained that could not
be assigned to the identified proteins, a secondary peptide mass
resolution 1D Western blot for comparison of the seroreactivities of melanoma patients and a healthy donor against the melanoma cell line M-NRT. In
contrast to the blots shown in panels A–E, the sera were applied 1/200 to isolated lanes from SDS-PAGE in sealed plastic bags which results in a better
definition of the bands when compared to blots from multiple blotting devices. Serum 18 is autologous to tumor cell line M-NRT, serum 7 is from a
different patient and serum 103 from a healthy donor. The arrows to the left of the lanes indicated antigen bands that are shared between the
patients and the healthy controls and occur in every blot. The arrows to the right of the lanes indicated prominent antigen that are detected only by
the sera of melanoma patients.
doi:10.1371/journal.pone.0005199.g001
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case could a second protein be identified indicating that the
analyzed spots did not contain major contaminating proteins. The
identified antigens can be grouped according to their cell
biological functions into different categories. Three of the antigens
are heat shock proteins (HSP60, HSP70 and HSP70 protein 9B), 7
are enzymes of the cellular metabolism (enolase I, dienoyl-CoA
reductase, aldolase A, fumarate hydratase, aldose reductase,
aconitase and lactate dehydrogenase), hnRNP-1 is a nuclear
protein involved in RNA processing, EF-Tu an elongation factor
in protein biosynthesis, MCP affiliated with the cytoskeleton and
involved in cell migration, calumenin a calcium-binding protein
involved in regulation of metabolic processes, VCP participates in
the regulation of protein export and the organization of the Golgi
apparatus, LAP3 and PSME1 are involved in protein metabolism,
and galectin-3 is a lectin with specificity for galactose. The
sequence coverage of the mass-spectrometric fingerprint analysis
of HnRNP is somewhat low. However, HnRNP had been
repeatedly identified from different gels with better sequence
coverage so that we are sure of its correct identification. For all
Figure 2. Seroreactivities of melanoma patients and healthy controls against antigens of the melanoma cell line M-NRT isolated by
2DE. Total protein extracts of M-NRT cells were separated with an isoelectric focusing pH range of 3–10 in the first and SDS-PAGE in the second
dimension, blotted onto nitrocellulose membranes and probed with the sera of the patients as listed in Table 1. Serum dilutions were 1/200. The
blots shown in Panels A through G were probed successively with 8 different patient sera each, blot H was probed with the sera of 9 healthy
controls. The arrows indicated the antigens that could be assigned to protein spots in the silver-stained gel show with Figure 3. The numbering for
the antigens is used throughout this report.
doi:10.1371/journal.pone.0005199.g002
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unequivocal identification of the corresponding proteins. Galectin
is extracellularly expressed and involved in various interactions
with serum proteins, other cells and extracellular matrix, and
variously implicated in cancer-related processes such as metastasis
formation and invasiveness. Enolase I, although a cytosolic
protein, has been reported to be exported and is found in the
extracellular environment of some tumors. Of the identified
antigens, galectin-3 and HSP60 most often induce antibody
responses in melanoma patients followed by calumenin and
Table 1. Serum combinations for 2-dimensional Western blot analyses and numbers of identified antigens.
Western blot #
{ Sera
{ Number of antigens
# Spot numbers of the identified
antigens*
In the Western
blots
Assigned to
proteins Identified
A 1, 2, 3, 6, 7, 10, 16, 18 26 17 14 1,4,5,9,12,13,21,23,24,27,28,29,30,31
B 4, 11, 13, 20, 21, 22, 23, 24 19 9 7 1,2,3,4,5,8,24
C 26, 29, 32, 34, 35, 47, 76, 79 21 4 4 3,4,5,9
D 36, 37, 38, 40, 43, 44, 46, 83 20 12 9 2,3,4,9,10,11,12,13,16
E 48, 49, 52, 53, 54, 55, 56, 91 24 9 6 1,2,3,4,9,19
F 9, 25, 60, 62, 63, 64, 65, 66 3 1 1 9
G 15, 57, 59, 85, 87, 90, 93, 100 15 4 3 2,9,10
H 102–110 4 2 2 3,4
{The numbering refers to the Western blots shown in Figure 2.
{The serum numbering refers to the serum numbers in Figure 1.
#The numbers of antigens correspond to the number of spots detected in the Western blots of Figure 2, of those assigned to protein spots in the silver-stained gel
shown with Figure 3 and the number of the assigned antigens that could be identified.
*The spot numbers correspond to the numbers of assigned antigen and protein spots indicated with arrows and numbered in Figures 2 and 3.
doi:10.1371/journal.pone.0005199.t001
Figure 3. Identification of melanoma-associated antigens detected by sera of melanoma patients. The protein spots that could be
assigned to antigen spots in the Western blots (arrows here and in Figure 2) were excised from the gels and treated with trypsin. The resulting
fragments were analyzed by mass spectrometry to identify the antigens. Eighteen different antigens were identified that were found in 46 different
spots in the Western blots shown in Figure 2.
doi:10.1371/journal.pone.0005199.g003
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detected in healthy donors tested.
Discussion
About two thirds of the 94 melanoma patients tested in this
study had mounted specific antibody responses against melanoma-
associated antigens with an average of about 3 antigens detectable
per seropositive patient. Only a few of the specific antigen bands
were shared between different patients and no two patients
displayed the same pattern of antigenicity. In highly resolving 2-
dimensional Western blots 128 antigens were detected with sera of
56 patients, i.e. an average of 2 to 3 antigens per patient. Four
antigens were also found with the sera of the healthy controls
which corresponds to an average of less than 0.5 antigens per
serum and is comparable to other studies done for cancer and
infectious diseases. Fifty-six of these antigens could be assigned to
protein spots in silver-stained gels and 44 of them identified by
mass spectrometry. They were found to represent 18 different
antigens, two, galectin-3 and HSP60, were found in 6 of the 7
Western blots, several more in between 2 and 5 blots but the
majority was detected only once. The serological immunoreactiv-
ities against the tumor cells, thus, are mostly heterogeneous.
Nonetheless, the majority of the patients had mounted antibody
responses against several antigens of the melanoma cell line tested
and some antigens raised responses in a relatively high proportion
of cases. For all antigens, the signals in the Western blots were
weak, despite high serum concentrations, indicating that the B cell
responses were weak. However, all these responses were
secondary, IgG responses, thus, depending on repeated stimula-
tion by the antigens and induction of MHC class II-restricted
CD4
+ helper T cells with specificity for the same antigens in order
to induce immunoglobulin class switch. These antigens, therefore,
are expected to harbor CD4 T cell epitopes as well as B cell
epitopes.
The identified antigens represent different cell-biological
categories of proteins including structural proteins (MCP),
metabolic enzymes (enolase 1, dienoyl-CoA reductase, aldolase
A, fumarate hydratase, aldose reductase, aconitase, LDH-H), heat
shock proteins (HSP60, HSP70, HSP70 protein 9B), proteins
involved in protein biosynthesis and protein metabolism
(HnRNP1, EF-Tu, PSMEI1, LAP3), a calcium-binding regulator
protein (calumenin) and a lectin of the outer membrane (galectin-
3). The prominence of metabolic enzymes among antigens
targeted by serological immune responses has also been reported
for patients with pancreatic, lung, renal, colon and hepatic cancers
[15,20,23–25,29]. As for the majority of other serologically defined
tumor-associated antigens identified so far, there is no recogniz-
Figure 4. Peptide mass fingerprint spectra of antigens identified by mass spectrometry. Panel A shows the mass spectrum of the tryptic
fragments for antigen spot number 9 identified as galectin-3, panel B the respective spectrum for antigen spot 1 identified as the actin filament
capping protein MCP, panel C antigen spot 4 identified as the heat shock protein HSP60 and panel D antigen spot 28 identified as the elongation
factor EF-Tu. The peptide mass fingerprint spectra for the other 17 antigen spots are provided with the supplementary materials indicated in Table 2
together with the statistics of the mass-spectrometric identification of the proteins. Asterisks indicate the tryptic fragment masses matched to the
database sequences of the proteins.
doi:10.1371/journal.pone.0005199.g004
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(www2.licr.org/CancerImmunomeDB). As judged from the pro-
tein gels, they do not grossly deviate in molecular masses and
isoelectric points from what is known for these proteins.
Comparative proteomics studies have shown that some of the
antigens may be overexpressed in tumor cells compared to their
normal counterparts [32,33]. Such overexpression may promote
immunogenicity of these proteins in cancer patients. With two
Table 2. Antigens recognized by sera of melanoma patients and identified by proteome serology.
Spot # Antigen (accession number) MW [kDa] pI
Number of
tryptic fragments Sequence coverage
PMF spectrum
Figure
total assigned
1 gelsolin-like actin filament-capping
protein MCP
38.5 5.88 26 17 42% 4
gi|63252913
2 enolase 1 47.1 7.01 76 28 59% S1
gi|29792061
3 calumenin 37.1 4.47 76 22 53% S2
gi|2809324
4 heat shock protein HSP60 61.0 5.70 52 32 57% 4
gi|31542947
5 heat shock protein HSP70 protein 8 70.9 5.37 84 36 49% S3
gi|5729877
8 2,4-dienoyl-CoA reductase 35.8 9.50 40 12 31% S4
gi|1575000
9 galectin-3 26.2 8.58 55 13 44% 4
gi|12654571
10 aldolase A 39.4 8.49 87 26 62% S5
gi|49456715
11 aldolase A 39.4 8.49 56 21 53% S6
gi|4930291
12 fumarate hydratase 54.6 8.85 82 26 41% S7
gi|32880021
13 fumarate hydratase 54.6 8.85 76 33 47% S8
gi|32880021
16 proteasome activator subunit 1 PSME1 28.7 5.78 55 20 57% S9
gi|5453990
19 aldose reductase 35.7 6.56 65 17 33% S10
gi|493797
21 heat shock protein HSP70 protein 9B 73.6 5.87 61 19 33% S11
gi|24234688
23 aconitase 2 84.0 7.20 61 38 47% S12
gi| 5304852
24 aconitase 2 85.5 7.62 82 50 57% S13
gi|20072188
27 nuclear protein HnRNP1 60.1 6.65 49 12 23% S14
gi| 52632383
28 elongation factor EF-Tu 49.5 7.70 52 17 35% 4
gi|55584035
29 valosin-containing protein VCP 89.3 5.14 43 24 28% S15
gi|6005942
30 LDH H 36.5 5.72 96 12 37% S16
gi|13786847
31 leucine aminopeptidase LAP3 56.0 7.58 84 28 56% S17
gi|4335941
doi:10.1371/journal.pone.0005199.t002
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directly accessible to the immune system. The one exception is
galectin-3. It is very interesting that seroreactivities for this
protein were found in 6 of the 7 Western blots suggesting that it
is a relatively dominant antigen and, maybe suited for targeted
therapy. The second, enolase, has been reported to be, under not
yet understood circumstances, exported from tumor cells. For
the other antigens it is likely that their immunogenicity is related
to destruction of tumor cells and their aberrant exposure to the
immune system.
Only one of the antigens reported herein, galectin-3, had
already been reported for melanoma [12]. Other antigens such as
EF-Tu, HSP70, HSP60, aldolase, fumarate hydratase, aldose
reductase, aconitase, HnRNP1, EF-TU, VCP and enolase have
been reported for other cancers including cutaneous T cell
lymphoma, and renal, hepatic, lung and pancreatic cancers but
not for melanoma [15,20,23–25,29,34,35]. The remaining
antigens appear to be new tumor-associated antigens. So far all
serologically defined antigens known for melanoma have been
identified by SEREX [9,12], and the SEREX database lists 102
melanoma-associated antigens (www2.licr.org/CancerImmuno-
meDB). Besides a number of unknown function and superfamily
affiliations, and some cancer/testis antigen [1,3,5,10], the vast
majority of the SEREX-defined melanoma-associated antigens
are of the same functional categories as those reported herein:
chaperones, metabolic enzymes, proteins involved in protein
biosynthesis and catabolism, structural proteins and regulators of
the cellular metabolism. Galectin-3, found by SEREX and in the
present study by proteome serology, is of great interest as it is
one of the very few serologically defined tumor-associated
antigens that are present at the outer cell surface. It has been
described as deregulated in different cancers and as involved in
cancer-related processes such as cell plasticity and vasculogenesis
[36–43]. Also enolase is exported and has been implicated in
cancer [44]. It had been identified as tumor-associated antigen in
renal cell carcinoma, lung squamous carcinoma, leukemia and
pancreatic ductal adenocarcinoma [23,24,29,45] (Novelli et al.
WO/2008/037792). These two proteins may be targets for
therapeutic intervention.
Proteome serology has been employed for antigen discovery for
renal cell carcinoma [24], breast cancer [21], colon carcinoma
[15,21], prostate cancer [26], pancreatic adenocarcinoma [20],
ovarian cancer [19], hepatocellular carcinoma [25], leukemia [45]
and lung squamous carcinoma [23,29]. While many of the specific
antigens reported for these cancers differ from those found for
melanoma, they do represent the same classes of proteins as
discussed above. On the other hand, there are antigens such as
galectin-3 that were found by proteome serology so far only for
melanoma, and others only for other cancers. Some of these
restricted antigens are ubiquitously expressed so that the basis for
their restricted antigenicity remains unclear. Very interesting is the
limited overlap of antigens discovered by SEREX and proteome
serology. This can not be explained by differences in the sensitivity
of these technologies as the more sensitive technology should
include also the antigens discovered by the less sensitive approach.
A possible explanation might be that these two technologies focus
on different sets of antigens: SEREX readily identifies mutated
antigens and antigens arising from splice variations but not post-
translational modifications. Proteome serology, on the other hand,
can detect proteins whose antigenicity is related to post-
translational modifications but mutations only when de novo
sequencing approaches are used instead of conventional protein
identification by peptide mass fingerprint [46,47]. The two
technologies thus are complementary.
Materials and Methods
Tumor cells, cell lines and sera
The tumor cells were isolated from melanoma metastases by
treating minced tissue with collagenase free of contaminating
protease activities and DNAse, passaging the resulting suspension
through a cell sieve to remove connective tissue, allowing the
tumor cells to adhere to tissue culture plastic plates and wash off
non-adherent cells. The tumor cells were harvested by scraping
them off the surface for direct use. Melanoma cell lines were
established from such primary cells by culturing in DMEM
(Gibco, Heidelberg) with 10% FCS (Biochrome, Berlin) and
pencillin/streptomycine (Gibco, Heidelberg) at 37uC with 8%
CO2. The cells were processed for electrophoretic analysis
immediately after harvest from the tumor nodules or from cell
cultures. The sera were collected from 94 patients with melanoma
at different stages of disease and 9 healthy donors of the same
average age. The study with human subjects had been reviewed
and approved by the institutional ethics committee of the Charite ´
– Universita ¨tsmedizin Berlin (Si. 277, September 11, 2003). The
materials were obtained and used with written informed consent of
the donors.
Protein sample preparation
The cells were collected by centrifugation at 1,6006g for
10 minutes at RT, washed three-times with PBS and solubilized
by a protocol adapted from Go ¨rg et al. [48] and Chan et al. [49]
with lysis buffer (7 M urea, 2 M thiourea, 2.5% Triton X-100, 2%
b-mercaptoethanol, 0.8% Pharmalyte pH 3.5–10 (LKB, Freiburg,
Germany), 200 mM PefablockH (Merck, Darmstadt), 1 mM
pepstatin (SIGMA, Munich, Germany) and 10 mM leupeptin
(SIGMA, Munich, Germany) by vortexing and sonication for
10 minutes in an ice cooled water bath. The cell extracts were
incubated for one hour at room temperature (RT) with 4,000 U/
ml benzonase (Merck, Darmstadt, Germany) to degrade nucleic
acids and then centrifuged at 350,0006ga t1 5 uC for 15 minutes.
The supernatants were collected, incubated once again with
Benzonase for 10 minutes at RT and cleared by ultracentrifuga-
tion as before.
Two-dimensional gel electrophoresis (2DE)
Isoelectric focusing (IEF) was run in immobilized pH-gradient
gel strips (IPG strips 180 mm63 mm; Pharmacia, Freiburg) with a
pH range of 3 to 10 [48,49]. About 100 mg protein, extract of
1610
6 cells in 350 ml solubilization buffer were loaded into an IPG
strip by in-gel re-swelling overnight at RT under silicon oil in a
nitrogen- and water-saturated atmosphere to prevent oxidation of
the protein and drying of the gel strips. The loaded strips were
rinsed, mounted on a cooled ceramic plate and connected to the
electrodes via water-wetted paper bridges. The IEF was run at
20uC under silicon oil in a nitrogen- and water-saturated
atmosphere with 0.15 mA per IPG strip and 50 V for 18 h,
150 V for 1 h, 300 V for 2 h, 600 V for 1 h, 3,500 V for 6.5 h
and 5,000 V for 3 h, a total of 40,000 Vh for pH 3–10 IPG strips.
After the run, the IPG-strips were stored at 220uC. For the second
dimension, IPG strips were thawed, rinsed with de-ionized water
and equilibrated to SDS-PAGE conditions for 15 minutes in 6 M
urea, 30% glycerol, 2% sodium dodecylsulfate (SDS), Tris pH 6.8
and bromophenol blue, 1% dithiothreitol (DTT) followed by
15 minutes in the same buffer but with 4% iodoacetamide instead
of DTT. The equilibrated IPG-strips were rinsed with de-ionized
water and placed gel-side to gel-side onto the 4.8% acrylamide,
0.13% bisacrylamide stacking gel of a horizontal SDS polyacryl-
amide gel with a 12.3% acrylamide, 0.34% bisacrylamide
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20 mA for 2–3 h for the pre-run to transfer the protein from the
IPG strip into the SDS polyacrylamid gel, followed by 1,000 V,
40 W and 40 mA for the separation until the running front
reached the anodic end of the gel.
Protein staining
The gels were stained with the high-sensitivity silver staining
approach by Blum and colleagues [50]. Briefly, SDS-PAGE gels
were fixed in 40% Methanol, 10% acetic acid for one hour or
overnight. Then, the gels were washed three times for
20 minutes in de-ionized water, sensitized for one minute in
0.02% sodium thiosulfate, washed three times for 20 seconds in
water and incubated for 20 minutes in silver staining solution
(0.2% silver nitrate, 0.0074% formaldehyde). After washing
three times for 20 seconds in water, the gels were incubated in
developing solution (6% sodium carbonate, 0.00015% formal-
dehyde, 0.0004% sodium thiosulfate) until protein spots became
visible. The reactions were stopped with 0.025% EDTA in
water.
Western blots
The proteins from unstained SDS-PAGE were transferred onto
nitrocellulose membranes (Schleicher & Schu ¨ll, Dassel, Ger-
many) by semi-dry blotting for 2 hours at 400 mA. Free binding
sites on the membranes were blocked with 5% low fat milk
powder in Tris-buffered saline (TBS) for one hour at room
temperature or at 4uC overnight. After blocking, the membranes
were incubated with patient sera at a 200-fold dilution for one
hour at room temperature, washed thrice for 10 minutes with
TBS and incubated for 30 min with alkaline phosphatase-labeled
anti human IgG (Anti-Human Ig-AP, Fab fragment; Boehringer
Mannheim) at a 5,000-fold dilution. After washing three times
10 minutes with TBS, the membranes were equilibrated to
developing buffer (100 mM NaCl, 100 mM Tris-HCl, pH 9.5)
and developed in the dark with 100 ml BCIP and 100 mlN B Ti n
100 ml developing buffer until antigen spots became visible. The
reactions were stopped by replacing the developing solution with
water. For 1-dimensional Western blots, the proteins of the
melanoma cells were separated by SDS-PAGE, 12% acrylamide,
0.8% bisacrylamide, blotted 1 h with 60 mA onto nitrocellulose
and processed as above. For detection of antigens, the sera were
applied in a multiple channel device (Figure 1A–E) or, after
cutting the blots into strips, in individual sealed plastic bags
(Figure 1F). Since efficient agitation of the serum solutions is not
possible in the multiple channel device and antigen binding is
solely dependent on diffusion, the sera had to be employed at a
high 6-fold dilution. For the blots developed as strips in
individual plastic bags, 200-fold dilutions of the sera were used
as for the 2D Western blots.
Matching antigens and protein spots
To match antigen spots in Western blots with the corresponding
protein spot in the silver-stained gel, the coordinates of the blots
and the gel were defined, first, with artificial spots at the corner
points, Ponceau S staining of the blot filter and aligning the spot
pattern with the spot pattern of the silver-stained gel and partial
blotting of a master gel and definition of marker spot sets, second,
definition of spot pattern in the local environments of the antigen
spots to match blots and gels in these local regions accurately,
third, comparing the sizes and shapes of the antigen and protein
spots and considering only those that are alike in these two
parameter.
In-gel digestion of protein
The protein spots were excised manually with a self-made spot
picker and de-stained as described by Gharadaghi and colleagues
[51] with 50 ml of Farmer’s reducing solution (15 mM potassium
ferricyanide and 50 mM sodium thiosulfate, both dissolved in
water), then washed three times for 5–10 minutes with 150 ml
water. Then the gel spots were soaked in acetonitrile and dried
under vacuum. The gel pieces were re-swollen in 7.5 mlo f5m M
ammonium bicarbonate with 75 ng of modified porcine trypsin
(sequencing grade, modified; Promega; Madison, USA) to
fragment the protein. After 10 minutes, 7.5 mlo f5 m M
ammonium bicarbonate were added and the solution with the
gel pieces incubated for at least 4 hours in a 37uC water bath. For
MS analysis, 1.5 ml of the aqueous supernatants were mixed
with 1 ml of 2,5-dihydroxybenzoic acid (DHB) (SIGMA,
Munich, Germany) (5 mg/ml water) directly on MALDI targets
(MTP AnchorChip 600/384, Bruker Daltronik, Bremen) and
air-dried.
Mass spectrometry
Mass spectrometric measurements were made with a Reflex IV
MALDI-TOF mass spectrometer (MS; Bruker Daltonik, Bremen)
in reflector mode at an acceleration voltage of 20 kV. The MS was
calibrated either with the external standards angiotensin II
(1046.5 Da), angiotensin I (1296.6 Da), bombesin (1619.8 Da),
substance P (1347.7 Da), ACTH 1–17 (2093.0 Da) and ACTH
18–39 (2465.1 Da) or with the autolytic 842.50 Da and
2211.10 Da trypsin fragments as internal standards. Monoisotopic
peptide masses were recorded. The spectra were processed by the
‘‘Xmass’’ software (Bruker Daltonik, Bremen) and the peaks
annotated automatically and checked manually. Post-source decay
(PSD) analyses were done in 10 sections for the entire mass range
and data accumulated from up to 300 shots per section. The peak
lists of the mass spectra were the basis for peptide mass fingerprint
analyses with the Mascot software (Matrix Science; http:www.
matrixscience.com/search_form_select.html) and profound
(prowl; http://prowl.rockefeller.edu/profound_bin/WebProFound.
exe) using the NCBI sequence database.
Supporting Information
Table S1 Patient data for the sera used in the study. Melanoma
patients and sera used for proteome-serological analysis of the
tumor-associated antigenicity in melanoma.
Found at: doi:10.1371/journal.pone.0005199.s001 (0.22 MB
DOC)
Figure S1 Peptide mass fingerprint spectrum of the protein in
gel spot 2: Enolase 1. Asterisks indicate fragment masses assigned
to the identified protein.
Found at: doi:10.1371/journal.pone.0005199.s002 (2.40 MB TIF)
Figure S2 Peptide mass fingerprint spectrum of the protein in
gel spot 3: Calumenin. Asterisks indicate fragment masses assigned
to the identified protein.
Found at: doi:10.1371/journal.pone.0005199.s003 (2.40 MB TIF)
Figure S3 Peptide mass fingerprint spectrum of the protein in
gel spot 5: HSP70 protein B. Asterisks indicate fragment masses
assigned to the identified protein.
Found at: doi:10.1371/journal.pone.0005199.s004 (2.32 MB TIF)
Figure S4 Peptide mass fingerprint spectrum of the protein in
gel spot 8: 2,4-dienoyl-CoA reductase. Asterisks indicate fragment
masses assigned to the identified protein.
Found at: doi:10.1371/journal.pone.0005199.s005 (2.33 MB TIF)
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gel spot 10: Aldolase A. Asterisks indicate fragment masses
assigned to the identified protein.
Found at: doi:10.1371/journal.pone.0005199.s006 (2.34 MB TIF)
Figure S6 Peptide mass fingerprint spectrum of the protein in
gel spot 11: Aldolase A. Asterisks indicate fragment masses
assigned to the identified protein.
Found at: doi:10.1371/journal.pone.0005199.s007 (2.32 MB TIF)
Figure S7 Peptide mass fingerprint spectrum of the protein in
gel spot 12: Fumarate hydratase. Asterisks indicate fragment
masses assigned to the identified protein.
Found at: doi:10.1371/journal.pone.0005199.s008 (2.34 MB TIF)
Figure S8 Peptide mass fingerprint spectrum of the protein in
gel spot 13: Fumarate hydratase. Asterisks indicate fragment
masses assigned to the identified protein.
Found at: doi:10.1371/journal.pone.0005199.s009 (2.36 MB TIF)
Figure S9 Peptide mass fingerprint spectrum of the protein in
gel spot 16: PSME1. Asterisks indicate fragment masses assigned
to the identified protein.
Found at: doi:10.1371/journal.pone.0005199.s010 (2.35 MB TIF)
Figure S10 Peptide mass fingerprint spectrum of the protein in
gel spot 19: Aldose reductase. Asterisks indicate fragment masses
assigned to the identified protein.
Found at: doi:10.1371/journal.pone.0005199.s011 (2.39 MB TIF)
Figure S11 Peptide mass fingerprint spectrum of the protein in
gel spot 21: HSP70 protein 9B. Asterisks indicate fragment masses
assigned to the identified protein.
Found at: doi:10.1371/journal.pone.0005199.s012 (2.28 MB TIF)
Figure S12 Peptide mass fingerprint spectrum of the protein in
gel spot 23: Aconitase 2. Asterisks indicate fragment masses
assigned to the identified protein.
Found at: doi:10.1371/journal.pone.0005199.s013 (2.29 MB TIF)
Figure S13 Peptide mass fingerprint spectrum of the protein in
gel spot 24: Aconitase 2. Asterisks indicate fragment masses
assigned to the identified protein.
Found at: doi:10.1371/journal.pone.0005199.s014 (2.29 MB TIF)
Figure S14 Peptide mass fingerprint spectrum of the protein in
gel spot 27: hnRNP1. Asterisks indicate fragment masses assigned
to the identified protein.
Found at: doi:10.1371/journal.pone.0005199.s015 (2.27 MB TIF)
Figure S15 Peptide mass fingerprint spectrum of the protein in
gel spot 29: VCP. Asterisks indicate fragment masses assigned to
the identified protein.
Found at: doi:10.1371/journal.pone.0005199.s016 (2.28 MB TIF)
Figure S16 Peptide mass fingerprint spectrum of the protein in
gel spot 30: LDH H. Asterisks indicate fragment masses assigned
to the identified protein.
Found at: doi:10.1371/journal.pone.0005199.s017 (2.49 MB TIF)
Figure S17 Peptide mass fingerprint spectrum of the protein in
gel spot 31: LAP3. Asterisks indicate fragment masses assigned to
the identified protein.
Found at: doi:10.1371/journal.pone.0005199.s018 (2.28 MB TIF)
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